A 72-year-old man was referred to our hospital for treatment of an ulcer that had been growing on his back for 10 years. Physical examination showed an ulcerated tumor from the neck to the back and 
Introduction
Metastatic basal cell carcinoma (MBCC) is rare, ranging from 0.0028 to 0.55% of basal cell carcinoma (BCC) cases 1 3 . No previous study has reported that MBCC can be effectively treated with a combination therapy of cisplatin and adriamycin. Evidence-based treatments for MBCC have not yet been established. Herein, we report a case of extensive MBCC in which an excellent response was achieved with chemotherapy.
Case Report
A 72-year-old man was referred to our hospital for treatment of an ulcer that had been growing on his back for 10 years. Physical examination revealed an ulcerated tumor from the upper part of the back to the cervical region, and swollen cervical lymph nodes ( Fig. 1-a and b) .
The tumor size was 12 9 cm. A red nodule, 1 cm in diameter, on his neck was located 5 cm from the ulcerated tumor ( Fig. 1-c) . The biopsy of the ulcerated tumor showed a nodular and morpheic BCC histologically ( Fig. 
1-d and e).
The red nodule was located in an area of subcutaneous tissue far from the primary tumor and was not continuous with the primary tumor pathologically, so we considered it to be a subcutaneous MBCC. Magnetic resonance imaging (MRI) showed a supraclavicular node and many enlarged cervical lymph nodes. A lymph node biopsy revealed BCC. Multiple bilateral lung nodules were detected by computed tomography (CT) (Fig. 2-a) .
A CT guided biopsy of the lung tumor revealed metastasis of the BCC. The primary ulcerated skin tumor was excised with a 1 cm margin, and total excision of the left cervical lymph node and subcutaneous tumor on the (
apy, a follow-up chest CT scan showed a 63.6% reduction in the size of the lung nodules ( Fig. 2-b) . Although a partial response was achieved after the 3 courses (Fig. 2-c and d), there was a recurrence of lung nodules in the lower lobe within 15 months (Fig. 2-e) . Following treatment with 8 courses of the therapy, the size of the nodules had not remarkably changed, and the chemotherapy was temporarily discontinued (Fig. 2-f (Fig. 3) . Immunohistochemical staining of the metastatic lesions, except in the lung, was positive for epithelial membrane antigen (EMA, monoclonal, Roche, Indianapolis, USA) and negative for anti-epithelial antigen (Ber-EP4, monoclonal, DAKO, Kyoto, Japan), whereas the primary skin lesion, lung metastatic lesion, and left cervical lymph node stained positive for Ber-EP4 and negative for EMA (data not shown). Diffuse alveolar damage was determined to be the cause of death.
Discussion
The important characteristics of our case were as follows:
1) BCC metastasis to the lung, lymph nodes and bone; 2)
The chemotherapy was effective in that it prolonged the life of the patient; 3) Autopsy revealed metastasis of BCC to several organs, a portion of which were compatible with BSC or metastatic SCC. Beadles 4 first described a patient with MBCC, Cortran 5 , Lattes and Kessler 6 described the diagnostic criteria for this condition, and our case was compatible with these criteria.
In Japan, to our knowledge, 58 cases were reported in the literature from 1980 through 2017. This original data was obtained from MEDLINE searches using PubMed or the Japan Medical Abstracts Society (ICHUSHI) database.
We compared the characteristics of these 58 Japanese BCC. The BCCs most commonly metastasized to the regional lymph nodes (63%), lungs (36%), bone (19%), and skin (12%). Seventy-four percent of the primary tumors were larger than 5 cm, the interval between the onset of tumor and metastasis was approximately 8.5 years, and the time to death after diagnosis of metastasis was approximately 28 months. BCC tumors more than 5 cm in diameter showed a 25% incidence of metastasis, which increased to 50% for lesions more than 10 cm in diameter 10 .
In this case, the histopathology of the primary skin tumor and lung and cervical lymph node metastases confirmed BCC, but the kidney, pancreas, several lymph nodes and liver had features of BSC or metastatic SCC.
Although the lymph nodes showed BCC at biopsy, they has been found to be as short as 8 months after the onset of metastatic disease without chemotherapy 9 .
In our case, a total of 10 courses of therapy were effective in slowing the progression of an MBCC tumor and extending the patient's life. Based on our patient, and past literature reviews, cisplatin and adriamycin combination therapy remains a key treatment with potential usefulness for at least some patients with MBCC.
